Dechert recently advised Aquestive Therapeutics on a $75 million strategic funding agreement with funds managed by RTW Investments, subject to United States Food and Drug Administration (FDA) approval of Anaphylm (epinephrine) Sublingual Film and other conditions.
This financing provides critical capital that will support Aquestive Therapeutics through 2027, enabling the company to bring Anaphylm to market, if approved by the FDA, and deliver a new treatment option for patients in need.
The Dechert team advising Aquestive was led by corporate and life sciences partner David S. Rosenthal, global finance partner Scott Zimmerman and counsel Meghan Redding, tax partner Joshua Milgrim and corporate associate Thomas Meriam.
